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An emerging field of research is starting to examine the association of infectious pathogens with type 2 diabetes mellitus (T2DM).
An understudied parasite of interest is Toxoplasma gondii. Globally, very few studies have been conducted to investigate this
association. Additionally, very little data exists on the prevalence of T. gondii in the general Australian population. Our group
sought to determine the prevalence, association, and risk factors between T. gondii infection and T2DM from a representative
Australian human population. Through a cross-sectional, age- and gender-matched case-control study, 150 subjects with T2DM
together with 150 control subjects from the Busselton Health Study cohort were investigated. Sera samples were tested for the
presence of anti-T. gondii IgG and IgM antibodies using enzyme-linked immunosorbent assays. Survey-derived data were also
analyzed to evaluate associated risk factors. The IgG seroprevalence was found to be 62% and 66% for the T2DM and control
groups, respectively (OR : 0:84; p = 0:471). IgM antibodies were detected in 5% of the T2DM patients and in 10% of the
controls (OR = 0:51; p = 0:135). There were no significant differences between male and female IgG seroprevalence rates for
both groups (OR : 0:88, 0.80; p = 0:723). The IgG seropositivity rate increased significantly in T2DM patients aged 45-84 years
in comparison to those aged 18-44 years (p < 0:05), but this was not observed in the control subjects. No risk factors were
associated with T. gondii seropositivity in both groups. The first Australian study of its kind found T. gondii infection in
Western Australia to be highly prevalent. The results also showed that there is no serological evidence of an association between
T. gondii infection and T2DM in the studied subjects. Australian health authorities should focus on raising awareness of
toxoplasma infection and target T. gondii transmission control. Further studies are needed to clarify the role of T. gondii in T2DM.
1. Introduction
Diabetes in Australia has reached an epidemic level with an
estimated 6% (1.2 million) of the adult population aged 18
years and over living with the condition [1, 2]. Diabetes is
also the sixth leading cause of death in Australia, responsible
for 10% of all deaths [3]. Themajority (86%) of Australian dia-
betics have type 2 diabetes mellitus (T2DM) with 172 new
cases being diagnosed each day [3]. In fact, diabetes is becom-
ing more common with the rate of prevalence more than dou-
bling from 1.5% to 4.7% between 1989-1990 and 2015-2016
[4]. If the incidence of diabetes continues to grow at the pres-
ent rates, there will be 2.5-3 million people with diabetes in
Australia by 2025 growing to 3.5 million by 2030 [4].
In 2016, 1.6 million deaths were caused by diabetes
worldwide [5]. This is mainly due to the increase in the
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numbers of people with T2DM as a result of the increase in
life expectancy, genetic predisposition, physical inactivity,
dietary changes, the obesity epidemic, and the decreased
mortality rates in diabetic individuals [1]. However, there
may also be additional unidentified novel risk factors, such
as subclinical inflammation caused by infectious agents, that
contribute to this rising prevalence of T2DM [6]. In this
regard, an emerging field of research is beginning to investi-
gate the potential of infectious and environmental pathogens
to cause low-grade inflammation that may facilitate the risk
and development of various metabolic conditions, including
diabetes and obesity.
Toxoplasma gondii (T. gondii) has been identified as
pathogen of potential interest in this field. Considered one
of the most successful human parasites [7], the Centers for
Disease Control and Prevention has prioritisedT. gondii as
one of the top “Five Neglected Parasitic Infections” due to
the severity of illness, high incidence, and potential for pre-
vention [8]. Humans acquire T. gondii infection by the inges-
tion of food, water, or soil contaminated by oocysts from the
definitive hosts, cats; consumption of raw/undercooked meat
and sausages which contains bradyzoites; or vertical trans-
mission of tachyzoites by transfusion, transplantation, or
ingestion of raw milk [9, 10]. It has also been hypothesized
that T. gondii may be transmitted via sexual contact [9].
The global prevalence rates of this parasite are phenomenal
with figures ranging from 15 to 85% depending on social
habits, climate condition, hygienic standards, and geograph-
ical regions [11].
Infection can be present with various nonspecific signs and
symptoms, but most are similar to general flu-like indicators
[12]. In all infections, specific antibodies to this parasite
remain detectable in the serum throughout the life of the host
[10]. Toxoplasma gondii can infect and replicate in any nucle-
ated host cells, leading to the production of various inflam-
matory markers via the innate acute inflammatory responses
and antigen-specific adaptive immunity. This facilitates a state
of chronic inflammation at various anatomical sites in the
host [13, 14]. Several reports have linked chronic T. gondii
infection to several autoimmune disorders such as thyroid
disease, systemic sclerosis, rheumatoid arthritis, and inflam-
matory bowel syndrome with several studies demonstrating
a positive correlation between T. gondii infection and numer-
ous neurological disorders and cancers [10–12, 15, 16].
However, T. gondii infection in individuals with T2DM
has received little recognition, and human studies investigat-
ing T. gondii infection in T2DM subjects are scarce. More-
over, there is very limited information on the prevalence,
incidence, and epidemiology of the disease in the general
Australian human population—perhaps because T. gondii
infection is not a notifiable disease in Australia and most T.
gondii infections are asymptomatic. The few previous studies
have reported prevalence rates amongst pregnant woman
throughout Australia between 23 and 35% [17–20]. Toxo-
plasma gondii latent infection has great potential as a novel
target for T2DM intervention and may pave a path for a
new field of study, “Toxoplasmic Type 2 Diabetes” [21, 22].
The objectives of this study were to (1) investigate the
possible serological relationship between T. gondii and
T2DM and (2) identify risk factors for T. gondii infection.
We undertook the first age- and gender-matched case-
control study in Australia by utilizing sera and cross-
sectional data (respiratory and chest conditions, various
disease states, anthropometric measurements, and laboratory
biochemical and haematological parameters) collected from
a community-dwelling cohort of adults attending the 2005-
2007 Busselton Health Survey in Western Australia.
2. Materials and Methods
The present study describes samples and data collected from
the residents of the inner-regional local government electoral
boundary of the City of Busselton, Western Australia, a cen-
tre for farming, vineyards, timber, tourism, and mineral
sands industries. A cross-sectional general population health
survey (Busselton Health Study, BHS) was conducted between
2005 and 2007 with participants recruited from the compul-
sory electoral role. This survey was conducted by the Busselton
Population Medical Research Institute (BPMRI), a promi-
nent biobank. Details on recruitment and study protocols
from this survey are described in Musk et al. [23]. Ethical
approval for the current analyses was obtained from the
Edith Cowan University Human Research Ethics Committee
(Project Number 16090).
2.1. Study Design. The design of the present study was a case-
control study in which the seroprevalence of T. gondii in sub-
jects with T2DM (n = 150) was measured and compared to
age- and gender-matched controls (non-T2DM, n = 150).
Clinical and demographic parameters were also investigated
for possible risk factor association. Sera were analyzed for
the presence of IgG and IgM antibodies against T. gondii
using commercially available qualitative ELISA methods
(Demeditec Diagnostics GmbH, Germany). These in-vitro
diagnostic assays have been designed for the qualitative
determination of specific IgG and IgM antibodies against
T. gondii in serum and plasma, and have claimed clinical
sensitivities and specificities of 99% and 98%, respectively,
for the IgG assay, and 99% and 100%, respectively, for the
IgM assay.
2.2. Criteria for Selection of Participants. Participants with
T2DM were defined as cases. T2DM was classified according
to the 1999 World Health Organization (WHO) Criteria
(fasting plasma glucose greater than or equal to 7.0mmol/L
and/or 2-hour plasma glucose greater than or equal to
11.1mmol/L) [24]. Healthy participants were defined as con-
trols by reference to the following criteria: (1) did not have a
documented medical diagnosis of diabetes, (2) were not tak-
ing any glucose-lowering medications, and (3) have fasting
and 2-hour glucose values below the diagnostic thresholds
for diabetes. In addition, subjects were screened for history
of treatment with psychoactive medication and were
excluded because of the previously reported and established
associations between positive T. gondii serology and numer-
ous forms of mental illnesses [15, 16].
2.3. Sample and Data Collection. The present study utilized
20μL of serum aliquoted from banked samples (stored at
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-80°C) that have been previously collected from study partic-
ipants aged 18-80 years attending the 2005-2007 BHS. Dur-
ing this survey, each participant completed a standard self-
administered questionnaire that obtained information on
respiratory and chest conditions and various disease states
and underwent a range of clinical tests including anthropo-
metric, respiratory, and cardiovascular measurements. Each
participant had a blood sample collected from the cubital
fossa in 10mL red top clot, 2mL purple top EDTA (ethylene-
diaminetetraacetic acid), and 2mL grey top FlOx (fluori-
de/oxalate) vacutainer tubes (BD Biosciences, Franklin
Lakes, New Jersey, USA) for laboratory biochemical and hae-
matological analyses which were conducted by PathWest
Laboratory Medicine-QEII Medical Centre, Nedlands, West-
ern Australia. The serum for the present study was aliquoted
and stored at -80°C until used.
2.4. Sample Integrity and Laboratory Analysis. To minimize
false positive or false negative results, lipemic, haemolysed,
icteric, or turbid (bacterially contaminated) samples were
excluded. Test samples were diluted 1 : 101 with ready-to-
use sample diluent (5 μL serum + 500 μL sample diluent).
The total volume of serum required from each subject to per-
form the IgG and IgM ELISAs was 20μL (5μL for IgG
ELISA, 5μL for IgM ELISA, and 10μL for repeat testing in
the event of an equivocal result). The case and control sera
were tested for anti-T. gondii IgG and anti-T. gondii IgM
antibodies using the Demeditec Diagnostics DETOX01
(IgG ELISA) and DETOX03 (IgM ELISA) kits according to
the manufacturers’ instructions. Briefly, these assays have
been designed for the qualitative evaluation of specific IgG
and IgM antibodies against toxoplasma in serum. The analy-
sis was performed double-blind to avoid result bias. Samples
from the female, male, T2DM, and control groups were ran-
domly mixed, and the analyst performing the analysis was
not aware of the source of samples. Then, 100μL of the
diluted (1 : 101) sample and the ready-to-use calibrators
(IgG [IU/mL]; A, 0; B, 10; C, 40; D, 100; E, 250; IgM
[U/mL]; A, 1; B, 10; C, 30; D, 120) were pipetted into each test
well (coated with T. gondii strain RH antigens, isolated from
infected mice, common to both the IgG and IgM assays) leav-
ing one well empty for the substrate blank. The plate was cov-
ered and incubated for 60 minutes at room temperature. The
wells were then washed three times with 300μL of diluted
washing solution using a Bio-Plex Pro II Microplate Wash
Station (Bio-Rad Laboratories, Berkeley, California). Subse-
quently, 100μL of ready-to-use conjugate was added into
each well except the substrate blank well. The plate was cov-
ered and incubated at room temperature for 30 minutes. This
was followed by another washing procedure as outlined
above, after which 100μL of the ready-to-use substrate was
pipetted into each well including the substrate blank well. A
final incubation phase for 20 minutes at room temperature
in the dark was performed before terminating the substrate
reaction with the addition of 100μL of the ready-to-use stop
solution into each well. The plate was then mixed and the
wiped in preparation for reading. This was performed using
a FLUOstar Omega microplate reader (BMG Labtech, Offen-
burg, Germany) at an absorption of 450nm. A standard
curve was generated by plotting the mean absorbance at
450 nm for each standard concentration (x-axis) against the
target antibody concentration (y-axis).
2.5. Qualitative Serology Interpretation. Results were deter-
mined qualitatively by comparing the calculated absorptions
for each sample serum with the value for the cutoff calibra-
tors (IgG, 10 IU/mL; IgM, 10U/mL). Values higher than
the cutoffs (IgG, 10 IU/mL; IgM, 10U/mL) were considered
positive, values less than the cutoffs were considered neg-
ative, while values falling within a grayzone of ±20% of
the cutoff values were considered equivocal and retested
once.
2.6. Statistical Analyses. Statistical calculations justifying the
sample sizes were performed using G∗Power V3.1.9.2
(Heinrich Heine University Düsseldorf, Germany). The fol-
lowing values were used: power of 95%; a 1 : 1 proportion of
cases and controls; and a reference seroprevalence of 50%
for the T2DM group and 30% for controls. Thus, a minimum
sample size of 139 cases and 139 controls was obtained and
rounded up to 150 subjects per group. Basic descriptive sta-
tistics including counts, means, standard deviations, and per-
centages were calculated for the control and T2DM groups
and their respective gender- and age- subgroups. Age was
divided into seven age groups: 18–34, 35–44, 45–54, 55–64,
65–74, 75–84, and 85 years and older. Seroprevalence rates
(%) of T. gondii including the odds ratios (OR) and corre-
sponding 95% confidence intervals (95% CI) were calculated.
The Fisher’s exact test was used to evaluate the seropreva-
lence values between case and control subjects with respect
to categorical variables to determine possible risk factor asso-
ciations. For continuous quantitative variables (laboratory
and anthropometric data), the normality of the data distribu-
tion was assessed using the Shapiro-Wilk test, Q-Q (quantile-
quantile) plots, and skewness and kurtosis values. As the
laboratory and anthropometric data were normally distrib-
uted, the parametric independent sample Student’s t-test
was used to compare the selected parameters between the
study groups. Correlation was assessed using the Pearson
correlation coefficient with p value and heat maps was gener-
ated to display the interrelationships between the laboratory
and anthropometric data within each study group. Probabil-
ity values were calculated on the basis of two-tailed tests. For
all analyses, a p value less than 0.05 was considered statisti-
cally significant. Data were analyzed using the Statistical
Package for Social Sciences (IBM® SPSS® Statistics version
25.0, Armonk, New York, USA).
3. Results
In this study, the case (n = 150) and control (n = 150) cohorts
were matched for age, gender, and age group distribution.
The mean age of the T2DM and control groups was 59:2 ±
15:1 and 58:4 ± 15:7 years, respectively. The mean duration
of T2DM was 6.8 years. Most of patients were in the 55–64
and 65-74 (n = 64) age groups, followed by the 45-54
(n = 62), 35-44, and 75-84 (n = 42) age groups. The basic
descriptive and biometric statistics are summarized in
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Table 1. As expected, T2DM subjects had significantly higher
weight, waist, and BMI measurements when compared to the
controls. The remainder of the baseline characteristics of the
study groups were not significantly different (p > 0:05).
3.1. Toxoplasma gondii, T2DM, and Associated Factors. From
the 150 subjects with T2DM, 93 (62.0%) were found to be
seropositive for anti-T. gondii IgG antibodies in comparison
to 99 (66.0%) of the 150 healthy control subjects. The differ-
ence between the two groups was not significant (OR : 0:84;
p = 0:470). Anti-T. gondii IgM antibodies were found in 8
(5.0%) of the T2DM patients and in 15 (10.0%) of the control
subjects. Again, the difference was not significant between
the two groups (OR = 0:51; p = 0:129) (Table 2).
Regarding the impact of gender, our results showed sim-
ilar seroprevalence rates of T. gondii IgG antibodies between
the female and male subjects belonging to the T2DM and
control groups. However, there was a significant difference
in the seroprevalence rate of T. gondii IgM antibodies
between the female T2DM group compared with the female
controls (4.0% and 17.3%, respectively; OR : 0:20; p = 0:008).
This was not observed within the male groups (Table 2).
Anti-T. gondii IgG seropositivity increased with age at
the rates of 0.97% and 0.57%, per year of age, for the
T2DM and control groups, respectively (Figure 1). In the
T2DM group, the 75-84 age group had the highest seroposi-
tivity rate at 76.2% (p = 0:011), followed by the 55-64 age
group (75.0%; p = 0:009), the 65-74 age group (71.9%;
p = 0:014), and the 45-54 age group (64.5%; p = 0:037),
whilst the lowest seropositivity of 22.2% was observed
in the 18-34 age group. In contrast, in the control subjects,
no significant relationship between increasing age and
increasing percentage of seropositivity for anti-T. gondii
IgG antibodies was observed. IgM was exuded from this
and further analyses due to the low number of seropositive
subjects.
A positive correlation was found between the duration of
T2DM and rate of T. gondii infection in that T2DM subjects
infected with T. gondii had been living with T2DM for longer
(average of 7.6 years, p = 0:044) and were older (average of
63.2 years old, p < 0:001) than their non-T. gondii-infected
T2DM counterparts whom would have been living with
T2DM for a shorter period (average of 5.6 years) and were
younger (average of 52.8 years old). Likewise, for the control
group, a similar trend was observed with infected subjects hav-
ing a higher average age than the uninfected subjects (average
of 60.9 and 54.5, respectively, p = 0:019) (Table 3).
Regarding pet ownership as a risk factor associated with
T. gondii infection, univariate analysis showed that owning
a cat, dog, and/or other pet was not significantly associated
with T. gondii infection. However, subjects with T2DM were
less likely than their matched controls to own a cat
(OR = 0:57, p = 0:140) or other pet (OR = 0:87, p = 0:721)
while the controls reported a higher rate of dog ownership
(OR = 1:32, p = 0:344) when compared to the T2DM sub-
jects. In addition, univariate analysis showed that body
mass index (BMI) among the selected disease states and
lifestyle factors (asthma, arthritis, bronchitis, cancer,
eczema, food allergies, hay fever, other chest conditions,
pleurisy, pneumonia, and sinusitis) were not identified as
risk factors associated with T. gondii infection (Table 2).
3.2. Laboratory and Anthropometric Analysis. Findings from
the laboratory and anthropometric studies are summarized
in Table 4. As expected, weight, BMI, and waist circumfer-
ence measurements were significantly higher in subjects with
T2DM in comparison to the control subjects (p < 0:01).
Results from laboratory investigations showed that elevated
white cell count (p = 0:016), lymphocyte count (p = 0:020),
neutrophil count (p = 0:039), glucose (p < 0:01), insulin
(p < 0:01), and triglyceride (p < 0:01) levels were signifi-
cantly associated with T2DM. However, T2DM subjects
had lower cholesterol (p = 0:033) and high-density lipopro-
tein (p < 0:01) results when compared to their control
counterparts.
When adjusted for T. gondii IgG seropositivity, it was
found that seropositive T2DM subjects had a significantly
lower red cell distribution width (RDW), a measure of the
variation in the size and volume of a patients red blood cells,
than seronegative individuals (average of 3.5 and 6.8, respec-
tively; p < 0:001). A similar trend was seen in the control
group where seropositive subjects had significantly lower
Table 1: Basic descriptive and biometric statistics for the study cohort comparing the case (T2DM subjects) and control (non-T2DM healthy
subjects) groups at baseline including age group stratification. BHS, Western Australia.
Parameter
T2DM
(n = 150)
Control
(n = 150) p
T2DM M
(n = 75)
Control M
(n = 75) p
T2DM F
(n = 75)
Control F
(n = 75) p
Average age (years) 59:2 ± 15:1 58:7 ± 15:8 N.S 63:9 ± 13:5 63:5 ± 14:5 N.S 54:6 ± 15:2 54:0 ± 15:8 N.S
Height (cm) 168:1 ± 9:1 168:4 ± 9:3 N.S 174:5 ± 6:7 173:9 ± 7:7 N.S 161:8 ± 6:5 163:0 ± 7:5 N.S
Weight (kg) 85:0 ± 18:5 77:2 ± 15:6 ∗∗ 90:0 ± 14:4 85:8 ± 13:8 ∗∗ 80:1 ± 20:5 68:6 ± 12:2 ∗∗
Waist (cm) 99:7 ± 14:8 91:3 ± 13:2 ∗∗ 104:6 ± 11:2 99:5 ± 10:2 ∗∗ 96:2 ± 16:7 83:3 ± 10:7 ∗∗
BMI (kg/m2) 30:0 ± 6:0 27:1 ± 4:5 ∗∗ 29:5 ± 4:1 28:4 ± 3:8 ∗∗ 30:5 ± 7:4 25:9 ± 4:9 ∗∗
Diabetes duration (years) 6:8 ± 5:8 — — 6:4 ± 4:6 — — 7:2 ± 6:8 —
Values are shown as mean ± standard deviation. M: male subjects; F: female subjects; n: number of subjects; cm: centimeter; kg: kilogram; BMI: body mass
index; kg/m2: kilogram force per square meter. Level of significance as estimated by the independent samples Student’s t-test: N.S: not significant; ∗p < 0:05;
∗∗p < 0:01.
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RDW values than seronegative individuals (average of 3.1
and 5.8, respectively; p < 0:01). Monocyte counts were also
lower in seropositive T2DM subjects (p = 0:044) while higher
neutrophil counts were observed in seropositive control sub-
jects (p = 0:032). The remaining anthropometric examina-
tions and laboratory results were comparable between the
study groups and no significant association with T. gondii
seropositivity was found (p > 0:05).
Correlation heat maps were generated to examine possi-
ble relationships between T. gondii seropositivity and the lab-
oratory and anthropometric determinations in the control
and T2DM study groups (Figures 2 and 3, respectively).
Table 2: Univariate analysis of the variables associated with the seroprevalence of anti-T. gondii IgG antibodies among T2DM patients and
control subjects. BHS, Western Australia.
Toxoplasma serology
OR 95% CI p valueT2DM (n, %) Controls (n, %)
POS NEG POS NEG
Gender (IgG)
Male 51 (68.0) 24 53 (70.7) 22 0.88 0.44-1.77 0.723
Female 42 (56.0) 33 46 (61.3) 29 0.80 0.42-1.54 0.507
Total 93 (62) 57 99 (66) 51 0.84 0.52-1.35 0.470
Gender (IgM)
Male 5 (6.7) 70 2 (2.7) 73 2.61 0.49-13.88 0.246
Female 3 (4.0) 72 13 (17.3) 62 0.20 0.05-0.73 0.008
Total 8 (5) 142 15 (10) 145 0.51 0.21-1.23 0.129
Health
SOB walking 19 74 11 88 2.05 0.92-4.59 0.076
Chronic cough 15 78 20 79 0.76 0.36-1.59 0.465
Chronic phlegm 16 77 15 84 1.16 0.54-2.51 0.699
Rhinitis 51 42 46 53 1.40 0.79-2.47 0.275
Wheeze 23 70 21 78 1.22 0.62-2.39 0.562
Chest tightness 27 66 19 80 1.72 0.88-3.37 0.110
Disease state
Asthma 20 73 20 79 1.08 0.54-2.17 0.824
Arthritis 42 51 36 63 1.44 0.81-2.57 0.215
Bronchitis 17 76 22 77 0.78 0.39-1.59 0.507
Cancer 4 89 4 95 1.07 0.26-4.40 0.938
Eczema 12 81 10 89 1.32 0.54-3.22 0.542
Food allergies 12 81 8 91 1.69 0.66-4.33 0.274
Hay fever 28 65 26 73 1.21 0.64-2.27 0.554
Other chest 12 81 10 89 1.32 0.54-3.22 0.542
Pleurisy 8 85 7 92 1.24 0.43-3.56 0.693
Pneumonia 17 76 18 81 1.01 0.48-2.10 0.996
Sinusitis 21 72 19 80 1.23 0.61-2.47 0.563
Pet ownership
Cat ownership 13 80 22 77 0.57 0.27-1.21 0.140
Dog ownership 41 52 37 62 1.32 0.74-2.35 0.344
Other pet ownership 16 77 19 80 0.87 0.42-1.82 0.721
Body mass index (BMI, kg/m2)
Underweight: <18.5 0 0 1 0 — — —
Normal: 18.5-24.9 11 10 30 20 0.73 0.26-2.05 0.553
Overweight: 25.0-29.9 40 22 44 16 0.66 0.66-1.43 0.293
Obese: >30.0 42 24 24 15 1.09 0.48-2.48 0.830
Waist
M> 102 cm, F > 88 cm 53 32 33 16 0.8 0.38-1.68 0.561
n: number of subjects; POS: number of subjects in which anti-IgG antibodies were detected; NEG: number of subjects in which anti-IgG antibodies were not
detected; OR: odds ratio; 95% CI: 95% confidence interval; SOB: shortness of breath; M: male; F: female.
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Moderate positive correlations were observed between creat-
inine and weight (r = 0:62, p < 0:01), body mass index (BMI,
r = 0:53, p < 0:01), waist circumference (r = 0:56, p < 0:01),
systolic blood pressure (SBP, r = 0:75, p < 0:01), hemoglobin
(Hb, r = 0:66, p < 0:01), hematocrit (Hct, r = 0:64, p < 0:01),
red cell count (RCC, r = 0:54, p < 0:05), and bilirubin
(r = 0:55, p < 0:01) in the control seronegative group but
not in the control seropositive group. However, in the control
seropositive group, creatinine correlated with red cell distri-
bution width (RCDW, r = 0:55, p < 0:05) which was not the
case for the seropositive group (r = 0:09).
Similarly, moderate positive relationships were noted
between creatinine and height (r = 0:73, p < 0:01), Hb
(r = 0:54, p < 0:05), and Hct (r = 0:51, p < 0:01) in the
T2DM seronegative group but not in the seropositive
group. However, a strong positive association between cre-
atinine and total protein was evident in the T2DM seropos-
itive group (r = 0:71, p < 0:01) but not in the seronegative
group (r = 0:20). All other parameters displayed correla-
tions of negligible magnitude between the T. gondii seropos-
itive and seronegative groups in the T2DM and control
cohorts.
4. Discussion
Globally, few studies have been conducted to explore the
association between T. gondii infection and diabetes with
conflicting reported results [25–32]. Based on the findings
of the present study, T. gondii infection appears very com-
mon in both T2DM patients and healthy non-T2DM control
subjects living in Busselton, Western Australia. Our investi-
gation showed that 62.0% of the subjects with T2DM and
66.0% of the healthy control subjects were seropositive for
anti-T. gondii IgG antibodies with no significant difference
observed between the two groups (p = 0:84). Therefore, the
findings of the present study do not support an association
between T2DM and T. gondii infection. Similarly, an Iranian
descriptive case-control study in which 150 diabetic patients
and 150 healthy individuals were tested for anti-T. gondii IgG
antibodies using an ELISA method found that 52.6% of dia-
betic patients were IgG seropositive compared to 50.6% of
the healthy individuals [25]. In addition, a recent age- and
gender-matched case-control study conducted in Mexico
also found no serological evidence of an association between
T. gondii infection and diabetes mellitus [26]. The authors
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Figure 1: Seroprevalence of anti-T. gondii IgG antibodies among patients with T2DM and control subjects, stratified by age group. BHS,
Western Australia. Average rate of seropositivity increase was calculated at 0.97% and 0.57%, per year of age, for the T2DM and control
groups, respectively. Error bars represent standard error of the respective proportions.
Table 3: Duration of diabetes in T2DM subjects with and without T. gondii infection as determined by IgG serology. Average age of T2DM
and control subjects with and without T. gondii infection as determined by IgG serology. BHS, Western Australia.
Toxoplasma IgG serology in T2DM subjects
p value
POS (n = 93) NEG (n = 57)
Duration of T2DM (years) 7:6 ± 6:2 5:6 ± 4:8 0.044
Age of subjects (years) 63:2 ± 13:0 52:8 ± 16:1 <0.001
Toxoplasma IgG serology in control subjects
POS (n = 99) NEG (n = 51)
Age of subjects (years) 60:9 ± 15:0 54:5 ± 16:7 0.019
Values are shown as mean ± standard deviation. POS: number of subjects in which anti-IgG antibodies were detected; NEG: number of subjects in which
anti-IgG antibodies were not detected.
6 Journal of Parasitology Research
reported low IgG seroprevalence rates of 6.4% (10/156) and
3.2% (5/150) in the diabetic and healthy groups, respectively
(OR : 2:06; 95%CI : 0:69 − 6:19; p = 0:18).
In contrast, studies that support an association between
T. gondii infection and diabetes all report significantly higher
seroprevalence rates of T. gondii infection in subjects with
diabetes when compared to the apparently healthy nondia-
betic individuals. It should be noted that all the investigations
originate from the Middle East and the majority include both
T1DM and T2DM patients in the case groups therefore pre-
venting direct comparisons to be made with the present
study: Molan et al., Iraq (diabetic, 300/450, 66.6%; control,
68/203, 33.4%; p = 0:009) [27], Hemida, Iraq (diabetic,
96/172, 55.8%; control, 38/98, 38.8%; p < 0:01) [28]; Saki
Table 4: Comparison of selected laboratory and anthropometric examinations, raw, and after adjustment for T. gondii infection status
between the T2DM (n = 150) and control groups (n = 150). BHS, Western Australia.
Parameter T2DM Control p
T2DM
p
Control
p
IgG POS IgG NEG IgG POS IgG NEG
Height (cm) 168:1 ± 9:1 168:4 ± 9:3 0.787 167:7 ± 9:4 168:9 ± 8:8 0.455 167:8 ± 9:8 169:7 ± 8:2 0.234
Weight (kg) 85:0 ± 18:4 77:2 ± 15:6 <0.01 85:5 ± 17:4 84:3 ± 20:0 0.704 77:1 ± 16:1 77:3 ± 14:5 0.963
BMI (kg/m2) 30:0 ± 6:0 27:1 ± 4:5 <0.01 30:4 ± 6:1 29:4 ± 5:9 0.307 27:3 ± 4:6 26:8 ± 4:4 0.490
Waist (cm) 100:4 ± 14:8 91:3 ± 13:2 <0.01 102:0 ± 13:7 97:8 ± 16:1 0.091 92:3 ± 12:8 89:4 ± 13:9 0.197
SBP (mmHg) 128:7 ± 19:9 124:3 ± 17:6 0.043 130:5 ± 20:1 125:8 ± 19:4 0.164 126:1 ± 17:9 120:8 ± 16:5 0.080
DBP (mmHg) 79:3 ± 9:7 77:4 ± 10:3 0.111 79:7 ± 9:7 78:5 ± 9:7 0.471 78:3 ± 10:7 75:7 ± 9:5 0.140
Hb (g/L) 145:8 ± 12:7 145:4 ± 13:0 0.764 147:1 ± 12:5 143:8 ± 12:8 0.123 145:8 ± 13:2 144:5 ± 12:8 0.547
Hct (L/L) 0:4 ± 0:0 0:4 ± 0:0 0.544 0:4 ± 0:0 0:4 ± 0:0 0.122 0:4 ± 0:0 0:4 ± 0:0 0.666
RCC^ 4:8 ± 0:4 4:7 ± 0:4 0.105 4:8 ± 0:4 4:8 ± 0:4 0.271 4:7 ± 0:5 4:7 ± 0:4 0.577
RDW (%) 4:8 ± 6:0 4:0 ± 5:8 0.296 3:5 ± 5:6 6:8 ± 6:2 <0.01 3:1 ± 5:4 5:8 ± 6:3 <0.01
WCC∗ 6:5 ± 2:1 6:0 ± 1:6 0.016 6:3 ± 1:7 6:9 ± 2:6 0.112 6:1 ± 1:5 5:7 ± 1:7 0.086
Lymph∗ (×1012/L8) 2:0 ± 0:5 1:8 ± 0:5 0.020 2:0 ± 0:6 2:0 ± 0:7 0.864 1:9 ± 0:6 1:8 ± 0:5 0.753
Mono∗ 0:5 ± 0:1 0:4 ± 0:1 0.051 0:4 ± 0:2 0:5 ± 0:1 0.044 0:4 ± 0:2 0:4 ± 0:1 0.579
Eosin∗ 0:2 ± 0:01 0:2 ± 0:01 0.735 0:2 ± 0:1 0:2 ± 0:1 0.824 0:2 ± 0:1 0:2 ± 0:1 0.401
Baso∗ 0:04 ± 0:03 0:04 ± 0:03 0.523 0:04 ± 0:04 0:04 ± 0:05 0.962 0:04 ± 0:03 0:03 ± 0:03 0.114
Neutro∗ 3:8 ± 1:2 3:5 ± 1:2 0.039 4:1 ± 1:9 3:6 ± 1:3 0.064 3:6 ± 1:2 3:2 ± 1:2 0.032
Platelets 246:4 ± 67:0 247:8 ± 61:7 0.849 239:2 ± 58:6 258:0 ± 77:9 0.096 244:4 ± 62:1 254:5 ± 61:0 0.348
MCV (fL) 88:8 ± 4:2 89:8 ± 3:9 0.041 89:0 ± 4:1 88:5 ± 4:3 0.448 89:7 ± 4:0 90:0 ± 3:9 0.699
TP (g/L) 74:7 ± 5:4 74:6 ± 3:8 0.833 75:0 ± 6:3 74:3 ± 3:5 0.460 74:8 ± 3:9 74:2 ± 3:5 0.413
Alb (g/L) 46:2 ± 3:4 45:7 ± 2:4 0.210 46:2 ± 3:8 46:1 ± 2:6 0.931 45:5 ± 2:6 46:3 ± 1:9 0.055
Bili (μmol/L) 9:9 ± 5:5 10:3 ± 5:4 0.587 10:1 ± 5:4 9:7 ± 5:6 0.633 10:8 ± 6:0 9:2 ± 3:7 0.087
Gluc (mmol/L) 6:8 ± 2:4 5:2 ± 0:5 <0.01 6:9 ± 2:6 6:5 ± 2:0 0.223 5:2 ± 0:5 5:1 ± 0:4 0.223
Insulin (mU/L) 13:3 ± 9:3 7:7 ± 5:4 <0.01 13:7 ± 9:3 12:6 ± 9:3 0.516 8:1 ± 6:0 6:9 ± 4:2 0.175
CRP (mg/L) 3:3 ± 4:4 2:5 ± 3:2 0.065 2:9 ± 2:9 4:0 ± 6:2 0.173 2:6 ± 2:8 2:4 ± 3:7 0.770
Chol (mmol/L) 5:2 ± 1:2 5:5 ± 1:0 0.033 5:2 ± 1:1 5:2 ± 1:2 0.923 5:5 ± 0:9 5:4 ± 1:0 0.400
HDL (mmol/L) 1:3 ± 0:4 1:6 ± 0:5 <0.01 1:3 ± 0:4 1:3 ± 0:4 0.637 1:6 ± 0:5 1:6 ± 0:5 0.898
LDL (mmol/L) 3:1 ± 1:0 3:3 ± 0:9 0.066 3:1 ± 1:0 3:0 ± 0:9 0.545 3:3 ± 0:8 3:2 ± 0:9 0.624
Trig (mmol/L) 1:8 ± 1:1 1:4 ± 0:6 <0.01 1:8 ± 0:9 1:9 ± 1:2 0.331 1:4 ± 0:7 1:3 ± 0:5 0.230
ALP (U/L) 72:8 ± 21:7 67:9 ± 21:6 0.051 75:5 ± 22:9 68:5 ± 18:9 0.055 66:8 ± 19:1 70:0 ± 25:7 0.390
ALT (U/L) 17:9 ± 2 5:0 14:0 ± 7:3 0.069 20:1 ± 30:8 14:4 ± 8:9 0.178 14:2 ± 7:8 13:7 ± 6:4 0.736
Creat (μmol/L) 77:4 ± 18:3 76:9 ± 17:4 0.883 81:1 ± 20:0 74:5 ± 16:6 0.199 77:7 ± 20:3 76:0 ± 14:6 0.766
Values are shown as mean ± standard deviation. T2DM: subjects with type 2 diabetes mellitus; n: number of subjects; +: subjects in which T. gondii IgG
antibodies were detected; -: subjects in which T. gondii IgG antibodies were not detected; BMI: body mass index; cm: centimeter; kg: kilogram; kg/m2:
kilogram force per square meter; SBP: systolic blood pressure; DBP: diastolic blood pressure; mmHg: millimeters of mercury; Hb: haemoglobin; Hct:
haematocrit; RCC: red cell count; RDW: red cell distribution width; WCC: white cell count; MCV: mean cell volume; TP: total protein; Alb: albumin; Bili:
bilirubin; Gluc: glucose; Chol: cholesterol; Trig: triglycerides; CRP: c-reactive protein; HDL: high-density lipoproteins; LDL: low-density lipoproteins; ALP:
alkaline phosphatase; ALT: alanine transaminase; Creat: creatinine. Units are recorded as absolute counts ∗(×109 cells/mL), or ^(×1012 cells/L).
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et al., Iran (diabetic, 47/110, 42.7%; control, 24/110, 21.8%;
p < 0:05) [29]; Shirabazou et al., Iran (diabetic, 55/91,
60.4%; control, 36/93, 38.0%; p < 0:001) [30]; Hemida et al.,
Egypt (T2DM, 14/37, 37.8%; control, 12/50, 24%; p = 0:04)
[31], and Gokce et al., Turkey (T2DM, 457/807, 56.6%; con-
trol, 56/250, 22.4%; p < 0:001) [32].
Recent systematic reviews and meta-analyses [22, 33, 34]
conducted to determine the possible association between T.
The colour indicates the general direction and strength of association (red = increase, blue = decrease).⁎Significant correlation, ⁎p < 0.05, ⁎⁎ p < 0.01.
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Figure 2: Correlation heat map with Pearson correlation coefficient values displaying the interrelationships between 37 laboratory and
anthropometric parameters in control subjects with and without T. gondii infection. BHS, Western Australia.
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Figure 3: Correlation heat map with Pearson correlation coefficient values displaying the interrelationships between 37 laboratory and
anthropometric parameters in T2DM subjects with and without T. gondii infection. BHS, Western Australia.
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gondii infection and diabetes mellitus concluded that T. gon-
dii is a possible risk factor for diabetes and that further inves-
tigation is recommended. However, the studies included in
these meta-analyses share common fundamental weaknesses,
especially if they are to be considered reference baseline stud-
ies. Firstly, there is a lack of standardisation with regard to
the criteria used to define various parameters, especially the
diagnosis of diabetes. This includes defining inclusion and
exclusion criteria consistent with the latest definitions of dia-
betes by the WHO. Secondly, there is no mention of having
excluded individuals with psychiatric conditions, including
personality disorders, from these studies (clinical heteroge-
neity). Thirdly, the studies were not comparable in their
methods of measuring T. gondii exposure, a fundamental fac-
tor that increases methodical heterogeneity. Lastly and per-
haps most importantly, there is noteworthy geographical
and demographic skew in favor of the Middle East. To this
extent, it is interesting to note that the only two studies out-
side of the Middle East, the present study and that of
Alvarado-Esquivel et al. [26] conducted in Mexico, both
found that no significant association between T. gondii infec-
tion and diabetes.
In the present study, domestic ownership of cats, dogs, or
other pets was not identified to be a risk factor associated
with T. gondii infection. Previous epidemiological studies
have reported similar observations [35, 36]. Although the
lack of an association of cat ownership may be surprising,
due to cats being biologically essential to the life cycle of T.
gondii as the only definitive hosts, contact with cats appears
to be a less important risk factor when compared to other
well-established risk factors such as contact with contami-
nated foods [25]. While data from other studies support cat
contact as a risk factor [37–39], prevention of T. gondii infec-
tion via cat exposure may be possible as cats only shed
oocysts for 1-3 periods in a lifetime. In addition, oocyst spor-
ulation can be avoided by regular removal of cat litter [40].
Hence, the results from the current study may indicate that
Australian cat owners are looking after their cats very well
with regard to their hygiene.
Although some studies have identified some factors such
as BMI and some diseases like cancer as risk factors associ-
ated with the infection with T. gondii [10, 25, 29, 39–41],
the results of the present study did not find any association
between the selected respiratory and chest conditions, vari-
ous disease states, or anthropometric measurements and T.
gondii infection in Western Australia. With respect to the
biochemical and haematological laboratory analyses, all
parameters except red cell distribution width (RDW) were
comparable, and no significant association with T. gondii
infection was found among the T2DM and control groups.
Significantly higher RDW values were found in T. gondii
seronegative subjects from both the T2DM and control
groups when compared to seropositive subjects (p < 0:01).
The RDW forms part of the standard laboratory full blood
count measuring the range of variation in red blood cell vol-
ume and recently, higher values have been associated with
various disease states including various forms of cancer
[42], carotid artery atherosclerosis [43], and metabolic syn-
drome [44]. Moreover, Patel et al. [45] conducted a mortality
follow-up study of 8,175 adults whose RDW values had been
previously recorded. They found that higher RDW were
strongly associated with an increased risk of death, and
RDW is a strong predictor of mortality. Further investigation
is warranted to confirm our findings and to explore the causes
of lower RDW values from subjects infected with T. gondii.
The strengths of the present study include a systematic
health screening process leading to a representative study
population including appropriate adjustment for gender
and age. Lastly, the associated factors were in majority envi-
ronmental factors hence specific factors like lifetime cat
exposure or lifetime undercooked meat consumption, that
were not available from the survey, should be investigated
in the future.
5. Conclusions
We conclude that T. gondii infection in Western Australia is
highly prevalent. There is no serological evidence of an asso-
ciation between T. gondii infection and T2DM in the studied
subjects in Busselton, Western Australia. Pet ownership,
amongst other parameters, was not identified as a risk factor
associated with T. gondii infection in T2DM and healthy sub-
jects. Toxoplasmosis has been neglected in Australian notifi-
able disease programs; therefore, public health authorities
should focus on raising awareness of Toxoplasma infection
and introduce public health programs targeting T. gondii
transmission control. Further studies are needed to clarify
the role of T. gondii in T2DM.
Data Availability
The datasets generated during the current study are available
from the corresponding author on reasonable request. The
pre-collected data analysed during this study are available
from The Busselton Population Medical Research Institute
but restrictions apply to the availability of these data, which
were used under specific approval for the current study,
and so are not publicly available.
Ethical Approval
This study is approved by the Human Research Ethics Com-
mittee of Edith Cowan University on 31 January 2017,
approval number: 16090.
Consent
Written informed consent was obtained from the study
participants.
Conflicts of Interest
The authors declare no conflict of interest.
Authors’ Contributions
All authors contributed to the conception and design of the
study. AM, KN, and WW obtained ethical approval. AM
and MH acquired the data. AM performed the laboratory
9Journal of Parasitology Research
analyses. AM, MS, JZ, and XM performed the statistical anal-
yses. AM andMH revised the draft manuscript for important
intellectual content. All authors reviewed and edited drafts
and approved the final manuscript for publication. All
authors agree to be accountable for all the aspects of the work
in ensuring that questions related to the accuracy or integrity
of any part of the work are appropriately investigated and
resolved.
Acknowledgments
This work was supported by the Joint Project of the Australian
National Health and Medical Research Council (NHMRC
APP1112767) and the National Natural Science Foundation
of China (NSFC 81561128020, 81573215). We thank the
School of Medical and Health Sciences at Edith Cowan
University, Joondalup, Western Australia.
References
[1] D. Australia, Diabetes: The Silent Pandemic and its Impact on
Australia, Diabetes Australia, 2012.
[2] International Diabetes Federation, IDF Diabetes Atlas, Inter-
national Diabetes Federation, Brussels, Belgium, 8th edition
edition, 2017.
[3] D. Australia, “NDSS national diabetes data snapshots: Type 2
Diabetes,” September 2018, https://www.ndss.com.au/data-
snapshots.
[4] D. J. Magliano, A. Peeters, T. Vos et al., “Projecting the burden
of diabetes in Australia-what is the size of the matter?,”Austra-
lian and New Zealand Journal of Public Health, vol. 33, no. 6,
pp. 540–543, 2009.
[5] World Health Organization, “Global Health estimates: deaths
by cause, age, sex and country, 2000–2016,” October 2018,
https://www.who.int/healthinfo/global_burden_disease/en/.
[6] A. Pradhan, “Obesity, metabolic syndrome, and type 2 diabe-
tes: inflammatory basis of glucose metabolic disorders,” Nutri-
tion Reviews, vol. 65, 12, Part 2, pp. S152–S156, 2007.
[7] Centers for Disease Control and Prevention, “Parasites-toxo-
plasmosis (toxoplasma infection),” October 2018, http://www
.cdc.gov/parasites/toxoplasmosis/epi.html.
[8] Centers for Disease Control and Prevention, “Neglected para-
sitic infections (NPIs) in the United States,” September 2018,
http://www.cdc.gov/parasites/npi/index.html.
[9] J. Flegr, K. Klapilová, and Š. Kaňková, “Toxoplasmosis can be a
sexually transmitted infection with serious clinical conse-
quences. Not all routes of infection are created equal,”Medical
Hypotheses, vol. 83, no. 3, pp. 286–289, 2014.
[10] W. Cong, G. H. Liu, Q. F. Meng et al., “Toxoplasma gondii
infection in cancer patients: prevalence, risk factors, genotypes
and association with clinical diagnosis,” Cancer Letters,
vol. 359, no. 2, pp. 307–313, 2015.
[11] J. P. Dubey, “The history of Toxoplasma gondii—the first 100
years,” The Journal of Eukaryotic Microbiology, vol. 55, no. 6,
pp. 467–475, 2008.
[12] F. Robert-Gangneux and M. L. Dardé, “Epidemiology of and
diagnostic strategies for toxoplasmosis,” Clinical Microbiology
Reviews, vol. 25, no. 2, pp. 264–296, 2012.
[13] J. Prandota, “T. gondii infection acquired during pregnancy
and/or after birth may be responsible for development of both
type 1 and 2 diabetes mellitus,” Journal of Diabetes andMetab-
olism, vol. 4, no. 2, 2013.
[14] S. Kankova, J. Flegr, and P. Calda, “An elevated blood glucose
level and increased incidence of gestational diabetes mellitus in
pregnant women with latent toxoplasmosis,” Folia Parasitolo-
gica, vol. 62, 2015.
[15] C. J. Carter, “Toxoplasmosis and polygenic disease susceptibil-
ity genes: extensive Toxoplasma gondii host/pathogen interac-
tome enrichment in nine psychiatric or neurological
disorders,” Journal of Pathogens, vol. 2013, Article ID
965046, 29 pages, 2013.
[16] S. A. Henriquez, R. Brett, J. Alexander, J. Pratt, and C. W. Rob-
erts, “Neuropsychiatric disease and Toxoplasma gondii infec-
tion,” Neuroimmunomodulation, vol. 16, no. 2, pp. 122–133,
2009.
[17] M. Kirk and K. Glass, “Foodborne illness in Australia: annual
incidence circa 2010,” September 2018, http://www.health
. g o v . a u / i n t e r n e t /ma i n / pub l i s h i n g . n s f / c on t e n t /
e829fa59a59677c0ca257d6a007d2c97/$file/wfoodborne-
illness-australia-circa-2010.docx.
[18] I. R.Walpole, N. Hodgen, and C. Bower, “Congenital toxoplas-
mosis: a large survey in western Australia,” The Medical Jour-
nal of Australia, vol. 154, no. 11, pp. 720–724, 1991.
[19] H. Karunajeewa, D. Siebert, R. Hammond, S. Garland, and
H. Kelly, “Seroprevalence of varicella zoster virus, parvovirus
B19 and Toxoplasma gondii in a Melbourne obstetric popula-
tion: implications for management,” The Australian and New
Zealand Journal of Obstetrics and Gynaecology, vol. 41, no. 1,
pp. 23–28, 2001.
[20] S. Berger, Toxoplasmosis: Global Status, GIDEON Informatics,
Los Angeles, USA, 2010 edition edition, 2010.
[21] A. Molan, K. Nosaka, M. Hunter, and W. Wang, “The role of
Toxoplasma gondii as a possible inflammatory agent in the
pathogenesis of type 2 diabetes mellitus in humans,” Family
Medicine and Community Health, vol. 4, no. 4, pp. 44–62, 2016.
[22] A. Molan, K. Nosaka, M. Hunter, and W. Wang, “A systemic
review andmeta-analysis of human case-control studies exam-
ining the association between Toxoplasma gondii and type 2
diabetes mellitus,” American Journal of Life Science Research,
vol. 6, no. 3, pp. 106–122, 2018.
[23] A. W. Musk, M. Knuiman, M. Hunter et al., “Patterns of air-
way disease and the clinical diagnosis of asthma in the Bussel-
ton population,” The European Respiratory Journal, vol. 38,
no. 5, pp. 1053–1059, 2011.
[24] World Health Organization Department of Noncommunic-
able Disease Surveillance, “Definition, diagnosis and classifica-
tion of diabetes mellitus and its complications,” September
2018, http://apps.who.int/iris/bitstream/10665/66040/1/
WHO_NCD_NCS_99.2.pdf.
[25] A. Siyadatpanah, F. Tabatabaie, H. Oormazdi et al., “Compar-
ison of anti–toxoplasma IgG and IgM antibodies determined
by ELISA method in diabetic and non–diabetic individuals in
west Mazandaran province Iran 2011–2012,” Annals of Biolog-
ical Research, vol. 4, pp. 281–285, 2013.
[26] C. Alvarado-Esquivel, N. Loera-Moncivais, J. Hernandez-
Tinoco et al., “Lack of association between toxoplasma gondii
infection and diabetes mellitus: a matched case-control study
in a Mexican population,” Journal of Clinical Medical
Research, vol. 9, no. 6, pp. 508–511, 2017.
[27] A. L. Molan and M. H. Ismail, “Study the possible associa-
tion between toxoplasmosis and diabetes mellitus in Iraq,”
10 Journal of Parasitology Research
World Journal of Pharmaceutical Sciences, vol. 6, pp. 85–96,
2017.
[28] E. Saheb, “Detection of toxoplasmosis infection in diabetic
patients,” Diyala Journal of Medicine, vol. 12, pp. 70–74, 2017.
[29] J. Saki, S. Shafieenia, and M. Foroutan-Rad, “Seroprevalence of
toxoplasmosis in diabetic pregnant women in southwestern of
Iran,” Journal of Parasitic Diseases, vol. 40, no. 4, pp. 1586–
1589, 2016.
[30] S. Shirbazou, A. Delpisheh, R. Mokhetari, and G. Tavakoli,
“Serologic detection of anti Toxoplasma gondii infection in
diabetic patients,” Iranian Red Crescent Medical Journal,
vol. 15, no. 8, pp. 701–703, 2013.
[31] M. H. Hemida, S. A. R. Shahat, A. M. S. Bayoumy, and K. A. H.
Mohammad, “Prevalence of toxoplasmosis among diabetic
patients,” European Journal of Pharmaceuticaland Medical
Research, vol. 4, pp. 137–140, 2017.
[32] C. Gocke, S. Yazar, F. Bayram, K. Gundogan, O. Yaman, and
I. Sahin, “Anti–Toxoplasma gondii antibodies in type 2 diabe-
tes,” The National Medical Journal of India, vol. 21, p. 51, 2008.
[33] H. Majidiani, S. Dalvand, A. Daryani, M. L. Galvan-Ramirez,
and M. Foroutan-Rad, “Is chronic toxoplasmosis a risk factor
for diabetes mellitus? A systematic review and meta-analysis
of case-control studies,” The Brazilian Journal of Infectious
Diseases, vol. 20, no. 6, pp. 605–609, 2016.
[34] A. Molan, K. Nosaka, M. Hunter, and W. Wang, “The associ-
ation between Toxoplasma gondii and type 2 diabetes mellitus:
a systematic review and meta-analysis of human case-control
studies,” Bulletin of the National Research Centre, vol. 44,
no. 1, 2020.
[35] E. Petersen, G. Vesco, S. Villari, and W. Buffolano, “What do
we know about risk factors for infection in humans with Toxo-
plasma gondii and how can we prevent infections?,” Zoonoses
and Public Health, vol. 57, no. 1, pp. 8–17, 2010.
[36] K. Boyer, D. Hill, E. Mui et al., “Unrecognized ingestion of
Toxoplasma gondii oocysts leads to congenital toxoplasmosis
and causes epidemics in North America,” Clinical Infectious
Diseases, vol. 53, no. 11, pp. 1081–1089, 2011.
[37] M. J. Yad Yad, N. Jomehzadeh, M. Jafar Sameri, and
N. Noorshahi, “Seroprevalence of anti-Toxoplasma gondii
antibodies among pregnant woman in South Khuzestan, Iran,”
Jundishapur Journal of Microbiology, vol. 7, no. 5, p. e9998,
2014.
[38] M. Baothman, F. Alserhan, A. Almunyif et al., “Prevalence of
Toxoplasma gondii infection in diabetic patients in Makkah
AL Mukarramah, Saudi Arabia,” Tropical Biomedicine,
vol. 35, pp. 464–471, 2018.
[39] M. M. Avelino, D. Campos Júnior, J. B. Parada, and A. M.
Castro, “Risk factors for Toxoplasma gondii infection in
women of childbearing age,” The Brazilian Journal of Infec-
tious Diseases, vol. 8, no. 2, pp. 164–174, 2004.
[40] J. P. Dubey, L. R. Ferreira, J. Martins, and J. L. Jones, “Sporula-
tion and survival of Toxoplasma gondii oocysts in different
types of commercial cat litter,” The Journal of Parasitology,
vol. 97, no. 5, pp. 751–754, 2011.
[41] A.-L. Molan and E. H. Rasheed, “Study the possible link
between toxoplasmosis and different kinds of cancer in Iraq,”
American Journal of Life Science Researches, vol. 4, no. 3,
pp. 83–88, 2016.
[42] T. S. Ellingsen, J. Lappegård, T. Skjelbakken, S. K. Brækkan,
and J. B. Hansen, “Impact of red cell distribution width on
future risk of cancer and all-cause mortality among cancer
patients–the Tromsø study,” Haematologica, vol. 100, no. 10,
pp. e387–e389, 2015.
[43] Y. Wen, “High red blood cell distribution width is closely asso-
ciated with risk of carotid artery atherosclerosis in patients
with hypertension,” Experimental and Clinical Cardiology,
vol. 15, no. 3, pp. 37–40, 2010.
[44] M. A. Sanchez-Chaparro, E. Calvo-Bonacho, A. Gonzalez-
Quintela et al., “Higher red blood cell distribution width is
associated with the metabolic syndrome: results of the Ibermu-
tuamur CArdiovascular RIsk assessment study,” Diabetes
Care, vol. 33, no. 3, pp. e40–e40, 2010.
[45] K. V. Patel, L. Ferrucci, W. B. Ershler, D. L. Longo, and J. M.
Guralnik, “Red blood cell distribution width and the risk of
death in middle-aged and older adults,” Archives of Internal
Medicine, vol. 169, no. 5, pp. 515–523, 2009.
11Journal of Parasitology Research
